Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data.
Majdoleen Al AlawnehOusama RachidIbtihal AbdallahAhmad MahfouzHazem F ElewaMohammed Ibn-Mas'ud DanjumaAsmaa Ezzeldin MohamedAhmed AwaisuPublished in: European journal of clinical pharmacology (2023)
Rivaroxaban prescribing has significantly increased over the years across general population, with a noticeable decline in obese population during the last few years (from 2018 onwards). Furthermore, an appreciable association was evident between all-cause mortality and BMI of these patients.
Keyphrases
- adipose tissue
- weight loss
- primary care
- metabolic syndrome
- venous thromboembolism
- type diabetes
- atrial fibrillation
- obese patients
- end stage renal disease
- pulmonary embolism
- newly diagnosed
- ejection fraction
- body mass index
- bariatric surgery
- prognostic factors
- stem cells
- adverse drug
- bone marrow
- mesenchymal stem cells
- machine learning
- insulin resistance
- weight gain